Anti-HPV 16 L1 monoclonal antibody (set)

Papillomaviruses are viruses that cause squamous epithelial and fibroepithelial tumors in their specific host species. In humans, human papillomaviruses (HPVs) can lead to both benign and malignant cell overgrowth, resulting in a wide range of clinical manifestations from genital warts to cervical cancer. HPV infection is the most common sexually transmitted disease, and over 4 types of HPV have been identified to infect the genital tract. Genital HPVs can be categorized as "low-risk" types such as HPV 6 and 11, or "high-risk" types including HPV 16, 18, 31, 33, 35, 39, 45, 52, and 58. The high-risk types are responsible for more than 95% of HPV-induced cervical cancer cases.
Preventing cervical cancer through vaccination is considered the most effective approach. Prophylactic HPV vaccines have shown efficacy in clinical trials against HPV infection, cervical intraepithelial neoplasia (CIN), and genital warts. However, these vaccines only target a few specific HPV types. The vaccines are based on papillomavirus-like particles (VLPs) composed of the major capsid protein, L1. VLPs consist of 36 copies of L1 protein arranged into 72 pentamers or capsomeres, forming structures that are immunologically similar to native virions. The VLPs induce a type-specific immune response, with minor cross-neutralization observed mainly between closely related HPV types. Structural analysis has revealed the presence of hypervariable loops on the outer surface of the capsid. Most HPV-neutralizing monoclonal antibodies identified to date are type-specific and recognize conformational epitopes within these surface-exposed hypervariable loops of the L1 protein. This specificity is due to the unique characteristics of each HPV type.

Figure 1. Vaccination against HPV infection using genotype-specific HPV L1 VLPs.
(Source: Berzofsky, J. A. et al., 2004)

Anti-HPV 16 L1 monoclonal antibodies are specialized antibodies designed to specifically recognize and bind to the L1 protein of HPV 16. They have significant applications in HPV research, diagnostics, and potentially targeted therapies. These antibodies help researchers understand the biology of HPV and provide potential avenues for developing novel interventions against HPV 16 infection and related diseases.

Anti-HPV 16 L1 monoclonal antibody
Anti-Human Papillomavirus 16 L1 monoclonal antibody
Anti-Human papillomavirus type 16 L1 monoclonal antibody
Anti-HPV16 major capsid protein L1 monoclonal antibody
Anti-Human Papilloma Virus Type 16 major capsid protein L1 monoclonal antibody